Nkarta, Inc. Net Change in Cash
Nkarta, Inc. (NKTX) reported Net Change in Cash of -$14.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-10
- Nkarta, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$12.28M, a 149.66% decline year-over-year.
- Nkarta, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $24.73M, a 88.72% decline year-over-year.
- Nkarta, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $219.25M, a 1255.71% increase year-over-year.
- Nkarta, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $16.17M.
- Nkarta, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $11.76M.
- Nkarta, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$3.17M.
- Nkarta, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$6.45M.
- Nkarta, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$22.68M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$14.68M 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | -$12.28M 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $11.76M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $32.24M 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $25.54M 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | $24.73M 10-Q · filed 2026-05-12 | ||||
| 2024-12-31 | -$3.17M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $25.92M 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | $89.36M 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | $219.25M 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | -$6.45M 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | $768.00K 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | -$8.38M 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $16.17M 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | -$22.68M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | -$20.52M 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | $70.83M 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | -$19.20M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | -$34.19M 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | $1.21M 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | -$72.23M 10-Q · filed 2022-08-11 | ||||
| 2021-03-31 | -$34.08M 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $76.23M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $168.11M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | -$2.71M 10-Q · filed 2021-08-12 | -$2.71M 10-Q · filed 2020-08-20 | |||
| 2020-03-31 | -$4.10M 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | $12.92M 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $31.41M 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | -$1.77M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |